M. Desch

发表

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

Glen R. Wunderlich, Viktoria Moschetti, M. Desch, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

Holger Rosenbrock, Glen R. Wunderlich, S. Ramael, 2018, Clinical and translational science.

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

Glen R. Wunderlich, T. Chan, M. Goettel, 2021, European journal of drug metabolism and pharmacokinetics.

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males

Glen R. Wunderlich, T. Chan, M. Desch, 2021, Clinical Drug Investigation.

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

R. Keefe, K. Nakagome, W. Fleischhacker, 2021, Lancet psychiatry.

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Glen R. Wunderlich, H. Schmitt, Viktoria Moschetti, 2018, Clinical Drug Investigation.

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

C. Kapitza, A. Hennige, D. Lamers, 2022, Diabetes, obesity & metabolism.

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

T. Chan, M. Goettel, M. Desch, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia

M. Desch, H. Rosenbrock, Glen Wunderlich, 2023, European Archives of Psychiatry and Clinical Neuroscience.

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

Viktoria Moschetti, M. Desch, Sophia Goetz, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates

F. Müller, K. Hohl, T. Chan, 2023, Journal of clinical psychopharmacology.